Hospital-Acquired Infections (HAI) Market, by Drug Class (Antibacterial Drugs, Antiviral Drugs, Anti

Published Date: July 2021 | Report Code : HC2169822


Hospital-Acquired Infections (HAI) Market, by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), Infection Type (Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, Hospital Acquired Pneumonia, Others), Product (Sterilizers, Disinfectors, Endoscope Reprocessors, Disinfectants, Medical Nonwovens), Testing Type (Microbial Testing Instruments, Reagents and Consumables, Infection Prevention and Surveillance Software), Application (Disease Testing, Drug-Resistance Testing), Technology (Phenotypic Methods, Genotypic Methods), End User (Hospitals and Intensive Care Units (ICUS), Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers, Others), and Region (North America, Europe, Asia Pacific, Middle East and Africa, South America) — Market Size and Forecasting to 2030

COVID-19 Impact : Our team has been closely monitoring the current developments to identify the potential impact of COVID-19 on stakeholders and business processes across the value chain of industries. A special section about COVID-19 will be covered with the report to help companies in defining sustainable strategies.

Domain : Healthcare

Report Code : HC2169822

Status : Published July 2021

The Hospital-Acquired Infections (HAI) Market reached USD 12,411.2 million in 2020 and it is projected to grow at a CAGR of 3.6% during the forecast period. The patients receiving treatment for medical or surgical conditions are vulnerable to hospital-acquired infections (HAIs), also known as nosocomial infections. The infection is caused due to exposure to other patients or negligence in maintaining a safe and secure hygienic environment in hospital or due to bacteria’s from used medical instruments and devices etc. HAIs occur in all settings of healthcare comprising hospitals, nursing homes, surgical centers, rehabilitation facilities, and ambulatory clinics.

According to the World Health Organization (WHO), nearly 30% of patients in ICUs are affected by hospital-acquired infections in high-income countries. In low- and middle-income countries, the frequency of hospital-acquired infections is at least 2─3 fold higher than in high-income countries. These infections are most prevalent in senior citizens in the ICUs as they are vulnerable to diseases and have a weak immune system. Newborns are also at a higher risk of acquiring hospital-acquired infections in developing countries with infection rates higher than the high-income countries as these regions have limited resources and have underdeveloped healthcare infrastructure.

A shift in government regulations regarding reimbursement for hospital-acquired infections has resulted in hospitals implementing required measures to reduce these infections. Lack of surveillance systems for healthcare-associated infections and lack of standardized criteria for diagnosing the infections has resulted in increasing prevalence of these infections. This has resulted in millions of patients being affected by hospital-associated infections around the world. Increasing adoption and implementation of innovative approaches in healthcare is expected to prevent the spread of hospital-acquired infections and reduce the cost burden of the hospitals. Increasing necessity of monitoring the data tracking for reducing infections has resulted in scientists and researchers collaborating with hospitals to invent new methods for disease detection.

For instance, in January 2021, researchers from the National Human Genome Research Institute (NHGRI), Oxford University, and other National Institutes of Health centers developed and tested a new method for preventing hospital-acquired infections. The researchers studied administrative data from 133,304 patients from 2011 and 2015 who stayed in National Health Service (NHS) hospitals in Oxfordshire, U.K. These patients had stayed in hospital for at least 48 hours. The researchers studied data and created a monitoring system that informed hospital administrators if patients’ co-presence with others warranted a test for potential infection. With the data, the researchers could predict infection due to bacterial and viral pathogens that cause HAIs.

The pandemic has increased the burden of offering efficient and quality treatment in the healthcare sector. Increasing prevalence of HAI infections is only adding more complications in the existing situation. The outbreak of COVID-19 has increased the risk of hospital-associated infections as COVID-19 patients require longer hospital stays. Violation of infection control procedures (IPC) by patients, hospital visitors, and hospital staff has led to an increasing prevalence of HAI globally. Along with COVID-19 patients, the people present in hospitals including, patients, staff, and others, are at risk of contracting HAI, which can have severe implications.

COVID-19 has accelerated the use of technology for maintaining hygiene, infection control, and monitoring patients. Applications of technology in reducing HAIs with the help of automated systems, which monitor and report hygiene adherence by healthcare professionals will assist the healthcare industry in reducing HAI. Cluster tracking helps track an infection to its origin and monitoring the immunization history, and tracking schedule of healthcare workers to assist in implementing preventive measures. Advanced technology integration, such as use of a germ-killing robot controlled by remote or an app will significantly reduce HAI.

For instance, in April 2021, Unimech Healthcare, a division of Unimech Aerospace and Manufacturing Pvt Ltd, announced the launch of UniClean, its array of solutions to prevent ‘Work Place Sickness’ and ‘Crowd Spread Infections’. UniClean with its cloud-based ultraviolet germicidal irradiation (UVGI) technology, provides 99.99% virus-free sterilization of air and surfaces in offices, industries, hospitals, malls, theatres, hotels, and restaurants.

Both public and private sector is promoting the use of advanced technology to control the hospital-acquired infections. For instance, in February 2021, the Government of Rwanda and the United Nations Development Programme (UNDP) launched disinfecting robots to fight the spread of COVID-19 and reduce hospital-acquired infections. The acquired UV-C robots have unique features, which include the UV-C lamps that emit ultraviolet lights destroying deadly microorganisms that could be missed during the manual cleaning process.

In January 2021, Joe DiMaggio Children's Hospital in the U.S. began piloting technology from intelligent observation. The acquired UV-C robots technology uses near-field magnetic induction (NFMI). It verifies if clinicians are washing or sanitizing their hands for proper amount of time at a scheduled time. NFMI has high accuracy and precision than previous technologies that rely upon radio-frequency identification (RFID) wireless technology.


table 1

Market Segmentation

The hospital-acquired infections market is segmented based on drug class, infection type, product, testing type, application, technology, end user, and region.


fig 1

Hospital-Acquired Infections Market, by Drug Class

Based on the drug class, the market is divided into antibacterial drugs, antiviral drugs, and antifungal drugs. Among these segments, the antibacterial drugs segment holds the largest market share in 2021 and is expected to remain the largest segment during the forecast period. The segment growth can be attributed to increasing use of antibacterial drugs that are active against the pathogens causing infections in hospitals and healthcare facilities. Antibacterial drugs fight against infectious bacteria by attacking the structure of the bacteria and its ability to reproduce in an individual’s body.

Hospital-Acquired Infections Market, by Infection Type

Based on infection type, the hospital-acquired infections market is divided into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, hospital acquired pneumonia, others.

Among these segments, the surgical site infections segment holds the largest market share in 2021 and is expected to remain the largest segment during the forecast period. The segment growth can be attributed to increasing cases of surgical site infection affecting operated patients in various healthcare settings with limited resources. This infection can be caused in case of poor post-operative recovery, increased post-operative morbidity, and mortality.

Examples of surgical site infections include purulent drainage from incision, isolated organisms from aseptically obtained fluid or tissue in incision. According to the Centers for Disease Control and Prevention (CDC), surgical site infections occur in 2–4% of all patients enduring inpatient surgical procedures.

Hospital-Acquired Infections Market, by Product

Based on product, the hospital-acquired infections market is divided into sterilizers, disinfectors, endoscope reprocessors, disinfectants, medical nonwovens.

Among these segments, the disinfectants segment holds the largest market share in 2021 and is expected to remain the largest segment during the forecast period. Disinfectants are used as the most important defense mechanism against HAIs. HAI prevention strategies range from hand hygiene using low-level disinfectants to the sterilization of medical devices using potent high-level disinfectants.

Hospital-Acquired Infections Market, by Testing Type

Based on testing type, the hospital-acquired infections market is divided into microbial testing instruments, reagents and consumables, infection prevention and surveillance software.

Among these segments, the microbial testing instruments segment holds the largest market share in 2021 and is expected to remain the largest segment during the forecast period. The segment growth can be due to increasing use of microbial detection for instruments to discover microbiological contamination.

Hospital-Acquired Infections Market, by Application

Based on application, the hospital-acquired infections market is divided into disease testing and drug-resistance testing.

Among these segments, the disease testing segment holds the largest market share in 2021 and is expected to remain the largest segment during the forecast period. The segment growth can be due to various tests carried out in a laboratory to establish or confirm a bacterial infection. Samples of body fluids reveal evidence and detect microbe causing the illness. The laboratory tests help the clinician to reach a diagnosis, which results in an increasing preference for disease testing.

Hospital-Acquired Infections Market, by Technology

Based on technology, the hospital-acquired infections market is divided into phenotypic methods and genotypic methods.

Among these segments, the genotypic methods segment is expected to be the fastest-growing segment during the forecast period. The genotypic method is emerging as a preferred method for establishing the identification of the bacteria in infections, which enables further diagnosis. This is expected to drive segment growth.

HAI can form biofilms in a patient, which leads to high resistance to several classes of antibiotics. As compared with phenotypic methods, genotypic methods are better at detecting this kind of bacteria resulting in increasing approval in the healthcare industry.

Hospital-Acquired Infections Market, by End User

Based on end user, the hospital-acquired infections market is divided into hospitals and ICUs, ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and others.

Among these segments, the hospitals and intensive care units (ICUs) segment holds the largest market share in 2021 and is expected to remain the largest segment during the forecast period. The segment growth can be attributed to increasing number of patients in the ICU receiving mechanical ventilator support and undergoing surgery. These patients are at greater risk from medical devices used in their treatment. The ICU patients have to stay in hospital for a long duration, which increases the risk of hospital-acquired infections.

Hospital-Acquired Infections Market, by Region

Based on region, the hospital-acquired infections (HAI) market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.

Among these regions, North America hospital-acquired infections (HAI) market holds the largest market share. The increasing government support promoting awareness initiatives regarding HAI along with carrying out discharge surveys are vital in reducing the prevalence of HAIs. For instance, in 2020, in U.S., the Department of Health and Human Services (HHS) announced the partnership for patients’ initiative to reduce HAIs. This initiative primarily focuses on HAIs through catheter-associated urinary tract infections, surgical site infections, bloodstream infections, and ventilator-associated pneumonia.

According to estimates from the Centers for Disease Control and Prevention, hospital-acquired infections (HAIs) lead to death of a significant number of people each year globally. The fatality rate is more than car accidents, breast cancer, or AIDS. It has increased the costs of the U.S. healthcare system by an estimated USD 30 billion-USD 45 billion each year.

Government rules and regulations such as the American Recovery and Reinvestment Act of 2009 offers funding to support states to prevent and reduce hospital-acquired infections. Many of these funds are being used to support activities to prevent hospital-acquired infections. It is also mandatory for healthcare facilities in the U.S. to improve the standards of disinfection and sterilization.

The Asia Pacific market is expected to grow at the fastest rate during the forecast period. Countries in the Asia Pacific have inadequate infection prevention and control surveillance systems and healthcare facilities have low accountabilities. The increasing prevalence of HAI has led to the implementation of preventive measures and initiatives with evidence-based strategies in the healthcare sector by public and private entities. For instance, in July 2019, the International Nosocomial Infection Control Consortium (INICC) partnered with Becton Dickinson (BD-India) to organize Heal-o-nomics.’ The program was designed to deal with the challenges of preventing HAIs and educate healthcare institutes and help offer better health care.

European market is expected to grow at a significant rate during the forecast period. In European countries, the prevalence of HAIs in ICUs is increasing rapidly. As healthcare becomes more complex and people become more resistant to antibiotics, the cases of HAIs are expected to increase. To reduce the HAIs, the companies are launching innovative products in the region to tap into the lucrative market opportunity in Europe. For instance, in March 2021, Innova Care Concepts partnered with Weber Hospital Systems to bring the Bed Washing System to the U.K. The launch aims to support continued efforts to reduce the number of healthcare-associated infections in the region.


table 2


fig 2

Recent Developments in the Global Hospital-Acquired Infections (HAI) Market

  • January 2021- Bactiguard launched Hydrocyn aqua (Hydrocyn) product range in Europe. The company entered into partnership with Lifecyn S.A. (Lifecyn) in Greece. The collaboration is based on an exclusive distribution agreement for Bactiguard’s Hydrocyn aqua range. The collaboration also includes products for advanced disinfection and wound care.
  • February 2021- Xenex launched Deactivate, a handheld LED UV solution intended to disinfect surfaces in confined spaces. Recognizing the need for targeted disinfection in small spaces and compact areas to deactivate pathogens, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.
  • March 2021- CARB-X is funding Affinivax, U.S., biotech company, to develop a new vaccine that will prevent Staphylococcus aureus (S. aureus) bacterial infections. The product will offer solution for healthcare-associated infections that are a major health threat particularly to high-risk and older patients.
  • June 2021- STERIS plc announced acquisition of Cantel Medical to extend STERIS’s product and service offerings to new global reach and customers.
  • June 2021- Kinnos chose the American Professionals in Infection Control (APIC) 2021 Conference to introduce its new healthcare-focused flagship product, Highlight for Bleach Wipes. These are disinfecting wipes that hospitals worldwide use for surfaces cleans.
  • June 2021- Foresight Group announced investment from the Midlands Engine Investment Fund (MEIF) into ReadyGo Diagnostics, a start-up diagnostics business. ReadyGo has created a pen-like gadget that can detect COVID-19. The gadget can be used to test for a variety of illnesses, including coronavirus and influenza, viral conjunctivitis, herpes, and dengue fever.
  • In October 2020- Olympus launched OER-Elite, an automated touchscreen endoscope reprocessor. The new product is a part of its infection prevention product portfolio. This extends the company’s automated endoscope reprocessor (AER) lineup.

What Does This Report Provide?

This report provides a detailed understanding of the hospital-acquired infections (HAI) market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market. The major market drivers, challenges, and opportunities for the hospital-acquired infections (HAI) market have been covered in the report. This report further includes the market shares of the leading companies operating in the global market, along with their production capacities and the growth strategies adopted by them.

Market Segmentation:

By Drug Class

  • Antibacterial Drugs
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • Others
  • Antiviral Drugs
  • Antifungal Drugs

By Infection Type

  • Urinary Tract Infections
  • Ventilator-associated Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Hospital Acquired Pneumonia
  • Others

By Product

  • Sterilizers 
  • Disinfectors 
  • Endoscope Reprocessors
  • Disinfectants
    • Hand Disinfectants
    • Skin Disinfectants
    • Instrument Disinfectants
    • Surface Disinfectants/Disinfectant Robots
  • Medical Nonwovens

By Testing Type

  • Microbial Testing Instruments
    • Automated Microbial Identification Systems
    • Polymerase Chain Reaction (PCR) Instruments
    • Mass Spectrometers
    • Microarrays
    • Polystainers
    • Flow Cytometers
    • Others
  • Reagents and Consumables
  • Infection Prevention and Surveillance Software

By Application

  • Disease Testing
  • Drug-Resistance Testing

By Technology

  • Phenotypic Methods
    • Phage-Based Assays
    • Colorimetric Methods
    • The Nitrate Reductase Assay
  • Genotypic Methods
    • DNA Sequencing
    • Solid-Phase Hybridization Techniques
    • Polymerase Chain Reaction Techniques
    • Microarrays

By End User

  • Hospitals and Intensive Care Units (ICUS)
  • Ambulatory Surgical and Diagnostic Centers 
  • Nursing Homes and Maternity Centers
  • Others

By Region:

North America Hospital-Acquired Infections Market

  • North America, by Country
    • U.S
    • Canada
    • Mexico
  • North America by Drug Class
  • North America by Infection Type
  • North America by Product
  • North America by Testing Type
  • North America by Application
  • North America by Technology
  • North America by End User

Europe Hospital-Acquired Infections Market

  • Europe, by Country
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe 
  • Europe by Drug Class
  • Europe by Infection Type
  • Europe by Product
  • Europe by Testing Type
  • Europe by Application
  • Europe by Technology
  • Europe by End User

Asia Pacific Hospital-Acquired Infections Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific 
  • Asia Pacific by Drug Class
  • Asia Pacific Infection Type
  • Asia Pacific by Product
  • Asia Pacific Testing Type
  • Asia Pacific by Application
  • Asia Pacific by Technology
  • Asia Pacific by End User

Middle East and Africa Hospital-Acquired Infections Market

  • Middle East and Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East and Africa
  • Middle East & Africa by Drug Class
  • Middle East & Africa by Infection Type
  • Middle East & Africa by Product
  • Middle East & Africa by Testing Type
  • Middle East & Africa by Application
  • Middle East & Africa by Technology
  • Middle East & Africa by End user

South America Hospital-Acquired Infections Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Rest of South America
  • South America by Drug Class
  • South America by Infection Type
  • South America by Product
  • South America by Testing Type
  • South America by Application
  • South America by Technology
  • South America by End User

Major Companies: The major companies of the market include Advanced Sterilization Products (Division Ethicon Us, LLC), Becton Dickinson and Company, Steris Corporation, Getinge Group, Kimberly-Clark Corporation, Cantel Medical, Biomerieux SA, Belimed AG, 3M Company, Sterigenics International LLC, Synergy Health, PLC, Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc.

Objectives of This Report:

  • To estimate the market size for the hospital-acquired infections market on a regional and global basis
  • To identify major segments in the hospital-acquired infections market and evaluate their market shares and demand
  • To provide a competitive scenario for the hospital-acquired infections market with major developments observed by the key companies in the historic years
  • To evaluate key factors governing the dynamics of hospital-acquired infections market with their potential gravity during the forecast period
  • To evaluate the leading company-wise pricing analysis for the mentioned applications

Key Questioned Answered in the Study:

  • What are major growth drivers and market trends that are affecting the hospital-acquired infections market?
  • What is the market size in terms of both value and volume for the hospital-acquired infections market?
  • Who are the leading market players and who are the new market players that operate in the hospital-acquired infections market with an estimated market share?
  • What are the future investment pockets and opportunity in the hospital-acquired infections market?
  • Major list of customers and potential futuristic customer list along with an estimated buying volume.
  • What will be the impact of COVID-19 on the hospital-acquired infections market?


This study is customized to meet your specific requirements:

  • By sub-segment
  • By client-specific country, type, and application market analysis
  • Pricing analysis along with the potential list of customers
  • Product-specific competitive analysis

For more information, contact: [email protected]

License Offering

Single User (PDF)


Multi User (PDF)


Enterprise User (PDF)


Get Regional Report @ USD 2000 Only

Your personal details are secure. Privacy Policy

Buy Chapters of Sections

Avail customized purchase options to meet your exact research needs.

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision


Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements

15% Free Customization

Share your Requirements

Questions?  Speak to an Analyst

Your personal details are secure. Privacy Policy